25 results about "Systolic function" patented technology

The invention discloses a left auricle plugging device provided with a real-time atrial pressure monitoring chip, and particularly relates to the technical field of left auricle plugging, the left auricle plugging device comprises a plugging device body and a connector, the top end of the connector is provided with a signal supply module, and the signal supply module is located in the plugging device body; according to the left atrial appendage plugging device, after the inductor in the nut generates a voltage signal, the signal can be transmitted to the low-noise operational amplifier and amplified, meanwhile, the electromagnetic interference between the noise of a circuit and the outside world is restrained, and the plugging device can be used for plugging the left atrial appendage of the left atrial appendage of the left atrial appendage. The physical deformation is converted into corresponding electric signals, the electric signals are transmitted to an in-vitro receiving terminal through an antenna, and a doctor can indirectly judge the recovery condition of the atrial contraction function of the patient according to the pressure signal trend.

The invention discloses a coronary artery hemodynamic information prediction method, device and equipment, a medium and a product, and relates to the field of biomechanics, and the method comprises the steps: obtaining clinical data, and segmenting the clinical data to obtain a coronary artery three-dimensional model and a heart three-dimensional model; constructing a human body blood circulation system lumped parameter model; determining a personalized human body blood circulation system lumped parameter model of the patient after assignment; constructing a 0-3-dimensional myocardial mechanical coupling model; constructing a first database; obtaining personalized systolic function parameters and diastolic function parameters of the patient based on the first mapping network; constructing a blood vessel 0-3-dimensional coupling model; constructing a second database; obtaining personalized coronary flow field information of the patient based on a second mapping network; the personalized coronary flow field information comprises a pressure field, a velocity field and concentration polarization characteristics of low-density lipoprotein on a blood vessel wall surface. Through network architecture innovation, the bottleneck of the model in the aspects of efficiency and personalization is solved, and the diagnosis precision of the coronary heart disease is improved.

The present invention discloses an anti-pulsation balloon fatigue testing device and its testing method, which includes a testing box body, a visualization cylinder body and a pneumatic pressure compensation device. The balloon is connected to a positive pressure regulating valve and a negative pressure regulating valve respectively through air pipes, and solenoid valves are used to control the air flow. When positive pressure is injected into the balloon, the solenoid valve controlling the positive pressure is opened, and the solenoid valve controlling the negative pressure is closed. Conversely, the solenoid valve controlling the positive pressure is closed, and the solenoid valve controlling the negative pressure is opened, so as to achieve the switching state of positive and negative pressures inside the balloon. The testing box body not only provides positive and negative pressures inside the balloon, but also can record the number of cycles. The present invention simulates the environment of blood vessels in the human body through the visualization cylinder body, and realizes the diastolic and systolic functions of the anti-pulsation balloon through the alternating cycle test of positive and negative pressures, so as to realize the fatigue test of the anti-pulsation balloon, and the test is more efficient.

The invention belongs to the technical field of biological medicine and molecular biology, and provides a hypertrophic cardiomyopathy virulence gene MYH7c.794Cgt; the invention relates to T (p.Thr265Ile) and an application thereof. The MYH7 gene mutation is located on the ninth exon, the 794th base is mutated from C to T, namely ACC is mutated to ATC, and the 265th amino acid in the coded amino acid sequence is mutated from threonine to isoleucine. The mutation induces cardiac hypertrophy by disrupting energy metabolism-this defect occurs prior to the occurrence of systolic dysfunction. Along with increasingly prominent status of precision medicine in cardiovascular treatment, a treatment strategy aiming at an upstream pathological process (such as energy homeostasis and mitochondrial dysfunction) provides a way with a wide prospect for preventing and treating MYH7-related hypertrophic cardiomyopathy. MYH7 gene screening has important values in the aspects of promoting early diagnosis, guiding timely treatment intervention and realizing risk-based prevention and management.

The invention discloses a method for constructing a chronic heart failure co-disease depression animal model through composite intervention, and belongs to the technical field of disease animal model construction. Firstly, a left anterior descending coronary branch ligation operation is performed on a mouse to construct a heart failure model, and then a depression model is constructed by constraining mouse superposition. After composite modeling, the systolic function of the mouse is obviously reduced, the activity ability is weakened, and myocardial fibrosis and hippocampal tissue damage occur, which indicates that the heart failure co-disease depression model is successfully modeled. The animal model construction method has a good application prospect in research on the pathogenesis, biomarkers and treatment means of heart failure co-disease depression.

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

The invention provides a method, a device, equipment, a readable storage medium and a program product for synchronous heart sound and electrocardio-assisted recognition of left ventricular systolic function reduction after STEMI, and belongs to the technical field of heart information collection and recognition. A method for identifying reduction of the left ventricular systolic function after STEMI assisted by synchronizing heart sound and electrocardio comprises the steps that heart sound signals and electrocardio signals of a human body are synchronously collected, and corresponding electrocardio data and heart sound data are obtained respectively; acquiring an electromechanical activation time parameter from a Q wave in the electrocardiogram data to a peak value of a first heart sound in the heart sound data; acquiring an RR period parameter of a time limit between two adjacent R waves corresponding to the electro-mechanical activation time in the electrocardio data; and calculating the ratio of the electromechanical activation time to the RR period, taking the ratio as an electromechanical activation time parameter standardized according to the heart rate, judging whether the ratio is greater than a preset threshold value or not, and if so, judging that the systolic function of the left ventricle of the collected person is reduced. The left ventricular systolic function can be detected in an auxiliary mode by synchronously collecting the heart sound and electrocardiosignals, the method is simple, and the cost is low.

The invention relates to application of arginine diester in preparation of a medicine for preventing and treating cardiovascular diseases, and belongs to the technical field of biological medicines. The invention provides an application of arginine diester in preparation of a medicine for preventing and treating cardiovascular diseases, the structural formula of the arginine diester is as shown in formula I, and y is 2, 3, 4 or 6. According to the arginine diester, the bioavailability of arginine in local cells of the heart is remarkably improved, the biological effect is more effectively played, and the arginine diester has higher heart targeting property and more effectively acts on heart tissues. The composition can significantly improve cardiac function indexes such as ejection fraction, short axis shortening rate and the like of the heart after myocardial infarction and ventricular remodeling, enhance the systolic function of the heart, improve cardiac hypertrophy, reduce the fibrosis area of the heart after myocardial infarction and increase the proportion of cardiac repair type macrophages after myocardial infarction, and is high in biological safety. The long-term treatment cost of cardiovascular diseases is reduced, the medical cost is reduced, and the overall health state and life quality of patients are improved.

The invention belongs to the field of new application of medicines, and particularly relates to application of Oloinab in preparation of medicines for treating and / or preventing ischemic cardiomyopathy. Animal experiments prove that Oloinab can remarkably improve the left ventricular ejection fraction and the left ventricular short axis shortening rate of myocardial infarction model mice, improve the heart function and reduce the cardiac fibrosis area, and it is indicated that Oloinab has the effect of improving myocardial remodeling and systolic dysfunction. The discovery provides a new treatment strategy for ischemic cardiomyopathy, and has an important clinical application prospect.

The invention provides a novel model for diagnosis and prognosis of sepsis cardiomyopathy and a construction method thereof. The element TMAD in the new model has the advantages that the element TMAD does not depend on the high cardiac hypersonic image quality and is easy and convenient to operate, no radiation or side effect exists, and the ventricular function can be accurately and rapidly evaluated; compared with LVEF sensitivity, the method has the advantages that left ventricular systolic function changes can be reflected earlier, measurement repeatability is quite good, and the method is particularly suitable for patients with poor cardiac ultrasound image quality; as a relatively new ventricular strain measurement technology, the ventricular strain can be obtained through further analysis by system software, the operation and software image analysis steps are simple, the ventricular strain can be skillfully applied through certain clinical training, the environment is not polluted, the health of an operator is not influenced, and the patient acceptability is relatively high; the method has high feasibility in diagnosis of sepsis cardiomyopathy.

The invention discloses an application of a verbascoside compound in preparation of a medicine for improving a cardiac function, and belongs to the technical field of biological medicines. The verbascoside disclosed by the invention has certain effects of regulating the cardiac diastolic and systolic functions of model mice, improving cardiac hemodynamics and protecting cardiac functions, has relatively good activity of reducing myocardial fibrosis, and can prevent cardiovascular complications induced by diabetes mellitus.

The present invention belongs to the technical field of biomedicine, and particularly relates to a recombinant vector expressing chromatin domain Y-like protein CDYL and its use. In order to screen key crotonyl-CoA metabolic enzymes in heart failure and provide a drug for treating heart failure, the present invention provides a recombinant vector expressing chromatin domain Y-like protein CDYL, which contains a gene encoding chromatin domain Y-like protein CDYL. The present invention also provides the use of the above recombinant vector in the preparation of a drug for preventing or treating heart failure. By overexpressing CDYL, it can improve the impaired cardiac systolic function caused by aortic arch constriction for 4 weeks, improve myocardial hypertrophy, myocardial fibrosis and heart failure, and can also reduce pathological myocardial cell hypertrophy. It can be used to prepare drugs for treating heart failure and has important practical significance.

Provided herein are methods, use, and compositions for treating systolic dysfunction such as heart failure with reduced ejection fraction.

Provided herein are methods, use, and compositions for treating systolic dysfunction such as heart failure with reduced ejection fraction.

The invention relates to the technical field of biological medicines, in particular to application of indole-3-lactic acid in preparation of a medicine for treating heart failure. The application potential of indole-3-lactic acid (ILA) in treatment of ejection fraction retention type heart failure (HFpEF) is proposed and verified for the first time. By constructing a mouse HFpEF model, researches prove that ILA can significantly improve the diastolic function of the heart, specifically, the E / E'ratio is significantly reduced, and meanwhile, the left ventricular ejection fraction and the short-axis shortening rate are not affected, which indicates that the ILA effectively relieves the core pathological feature-diastolic dysfunction of the HFpEF on the basis of maintaining the systolic function of the heart.

The invention provides a simulated jellyfish-based plateau environment systolic function model, which comprises a jellyfish-shaped framework and a cardiac muscle tissue layer cultured on the jellyfish-shaped framework, and is used for simulating the systolic function of the heart through spontaneous or rhythmic systole; the pacing point and conduction system consists of a patterned myocardial cell layer and is used for generating and / or conducting an electric signal to stimulate rhythmic contraction / relaxation of a myocardial tissue layer; the balance weight is arranged at the bottom of the center of the jellyfish-shaped frame and used for enabling the gravity borne by the simulated jellyfish in the culture solution to be larger than the buoyancy borne by the simulated jellyfish. The invention also provides a simulated jellyfish-based plateau environment systolic function simulation and detection system, and the simulated jellyfish-based plateau environment systolic function model is used as a bionic simulator and is used for analyzing the motion state, tissue pathology and metabolism conditions of the bionic simulator in a body blood component culture solution in a simulated plateau environment. And evaluating the influence of the culture solution on the heart function.

This invention discloses the medical use of AMPKγ2 protein for preventing or treating heart failure (HF) after myocardial infarction (MI), belonging to the field of pharmaceutical biotechnology. The expression level of AMPKγ2 protein or its active fragment is correlated with HF caused by abnormal cardiac remodeling due to excessive inflammatory response after MI. MI mice with systemic AMPKγ2 knockout significantly decreased left ventricular systolic function and significantly increased macrophage infiltration; whereas MI mice with systemic AMPKγ2 overexpression showed reduced cardiac dysfunction due to MI and macrophage infiltration. Furthermore, macrophage-specific knockout of AMPKγ2 exacerbated cardiac dysfunction due to MI and macrophage infiltration; conversely, macrophage-specific overexpression of AMPKγ2 alleviated cardiac dysfunction due to MI and macrophage infiltration. This invention provides a new target for the diagnosis and treatment of HF after MI and has significant clinical significance.

The invention belongs to the technical field of biological medicines, and discloses application of phellandrene in preparation of right ventricle targeted hypoxic pulmonary hypertension prevention and treatment medicines. The specifically related alpha-phellandrene can be used for improving organ indexes, relieving right ventricular function damage caused by hypoxic pulmonary hypertension, reducing average pulmonary hypertension, and reducing right ventricular hypertrophy and right heart weight index; under the guidance of the application of phellandrene in preparation of the right ventricle targeted medicine for preventing and treating hypoxic pulmonary hypertension, the developed right ventricle targeted medicine can directly act on the right ventricle, the burden of the right ventricle is relieved, and the compliance and systolic function of the right ventricle are improved, so that the disease progress is delayed, and the curative effect of the right ventricle is improved. The exercise endurance and the life quality of the patient are improved.

Described herein are compositions comprising viral vectors. The viral vectors can encode a tubulin organizing protein or peptide, such as a cardiac isoform of bridging integrator 1 (cBIN1). Also disclosed herein are methods of treating or preventing heart failure in a subject in need thereof. The methods of treatment or prevention can comprise administering a vector comprising cBIN1 to a subject who has experienced heart failure or who has chronic myocardial stress, to repair or enhance contractile (systolic) function or relaxation (diastolic) function in the subject's heart.

The application discloses application of raloxifene or a pharmaceutical salt thereof in preparation of a medicine for treating sepsis cardiomyopathy, and simultaneously discloses application of a STAT3 protein Tyr705 site as a sepsis cardiomyopathy treatment target, and belongs to the technical field of biological medicines. The application proves through in-vivo and in-vitro experiments that raloxifene can effectively improve body temperature drop and left ventricular systolic function reduction related to sepsis cardiomyopathy, reduce myocardial inflammatory infiltration, relieve myocardial oxidative stress, mitochondrial dysfunction and energy metabolism disorder, and play a definite myocardial protection role by inhibiting phosphorylation activation of the STAT3 protein Tyr705 site in myocardial tissue and cells. The application provides a novel targeted treatment strategy and drug selection for sepsis cardiomyopathy, and has a good clinical transformation application prospect.

The invention discloses application of triethylene tetramine in preparation of a medicine for treating or preventing sepsis complications. Researches show that triethylene tetramine (TETA) can reduce the cardiac systolic function caused by lipopolysaccharide (LPS), and the damage to the mitochondrial structure of myocardial tissue is improved to a certain extent; the TETA also shows that the TETA can improve alveolar interval thickening, pulmonary edema, increase of protein concentration and lactic dehydrogenase activity in alveolar lavage fluid, formation of inflammasome, pyroptosis and the like caused by the LPS to a certain extent; the triethylene tetramine can inhibit expression of inflammatory factors in myocardial tissue and lung tissue, the effect of the triethylene tetramine in treatment or prevention of sepsis complications (sepsis cardiomyopathy and sepsis acute lung injury) is indicated, a new treatment choice is provided for sepsis patients, and the triethylene tetramine has important clinical application value.

The invention relates to an intelligent auxiliary system for left ventricular systolic function evaluation and application, and belongs to the technical field of medical instruments. The system comprises a data acquisition module, a standard evaluation module, a processing module and a data processing module, wherein the data acquisition module is used for acquiring DICOM (Digital Imaging and Communications in Medicine) format image data of a human heart left ventricle transthoracic echocardiogram; the data processing module comprises a left ventricular systolic function calculating device and is used for processing the left ventricular transthoracic ultrasonic image of the human heart and obtaining a left ventricular systolic function value; the computing device comprises a plurality of program codes, acquires image data of the TTE along with execution of the program codes, analyzes the ultrasound image data on the basis of pre-learned deep neural network model data, obtains a numerical value of the left ventricular systolic function, and guides formulation of a clinical treatment scheme.

The present disclosure features compositions and methods for modulating mammalian muscle contraction. The present disclosure also features compositions and methods for the treatment of a cardiac disease or disorder (e.g., a cardiac disorder involving abnormal force production and / or cessation in cardiac muscle, cardiac hypertrophy, reduced systolic function, reduced diastolic function, maladaptive hypertrophy, heart failure with preserved systolic function, diastolic heart failure, systolic heart failure, hypertensive heart disease, aortic and mitral valve disease, pulmonary valve disease, hypertrophic cardiomyopathy, post ischemic and post-infarction cardiac remodeling, or cardiac failure) in a subject. The methods involve administering flightin polypeptides and / or WYR polypeptides, or polynucleotides encoding the same, as described herein.

A system and method for prolonged organ preservation and real-time ex-vivo organ assessment. The organ perfusion and assessment system includes three components: A full cardiac output circuit, a resuscitation and low flow circuit, and an organ indexing stack to perform real-time hemodynamic ex-vivo organ assessment. A containment vessel maintains sterility and allows for complete echo-analysis. The slope of preload recruitable stroke work (PRSW) and other load-independent and load-dependent assays are used to stratify donor heart function. The best assessment of systolic function and therefore transplant suitability appears to be PRSW; the best systolic function is seen with full support of a donor heart. The best assessment of diastolic dysfunction appears to be Tau; the best diastolic function is also seen with full support of a donor organ. Load independent assessments appear to be highly repeatable and should identify currently discarded human donor hearts that are actually suitable for transplantation.